+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Agoraphobia Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4767495
  • Report
  • April 2019
  • Region: Global
  • 65 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Dexcel PT Holdings Ltd
  • Eli Lilly and Co
  • Mylan NV
  • Pfizer Inc
  • Syneos Health Inc
  • The Lundbeck Foundation
  • MORE
The global clinical trial report- “2019 Agoraphobia Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Agoraphobia. It presents in-depth analysis of Agoraphobia clinical trials across markets and companies. The research work is for providing complete understanding into trends in Agoraphobia.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Agoraphobia clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Agoraphobia

The research work is prepared through extensive and continuous research on Agoraphobia trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Agoraphobia patients are identified
  • The report includes panorama of Agoraphobia clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Agoraphobia clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Dexcel PT Holdings Ltd
  • Eli Lilly and Co
  • Mylan NV
  • Pfizer Inc
  • Syneos Health Inc
  • The Lundbeck Foundation
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Agoraphobia Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Agoraphobia Clinical Trials by Region
2.2.2 Average Enrollment of Agoraphobia Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Agoraphobia Treatment, 2019

3. Region wise Agoraphobia Clinical Trials
3.1 Asia Pacific Agoraphobia Clinical Trials by Country
3.2 Europe Agoraphobia Clinical Trials by Country
3.3 North America Agoraphobia Clinical Trials by Country
3.4 Middle East and Africa Agoraphobia Clinical Trials by Country
3.5 South and Central America Agoraphobia Clinical Trials by Country

4. Agoraphobia Clinical Trial Trends
4.1 Start Year wise Agoraphobia Clinical Trials
4.2 Phase wise Agoraphobia Clinical Trials
4.3 Trial Status wise Agoraphobia Clinical Trials
4.4 Trial Type wise Agoraphobia Clinical Trials

5. Agoraphobia Average Enrollment Trends
5.1 Average Enrollment in Agoraphobia Trials by Year
5.2 Average Enrollment in Agoraphobia Trials by Phase
5.3 Average Enrollment in Agoraphobia Trials by Status
5.4 Average Enrollment in Agoraphobia Trials by Type of Trial

6. Companies Participating in Agoraphobia Clinical Trials
6.1 Agoraphobia Trials by Sponsor Type
6.2 Agoraphobia Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Agoraphobia Trials- Phase 1
7.2 Agoraphobia Trials- Phase 2
7.3 Agoraphobia Trials- Phase 3
7.4 Agoraphobia Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Agoraphobia Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Agoraphobia Clinical Trials and Enrolment
Figure 5: Europe - Country wise Agoraphobia Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Agoraphobia Clinical Trials and Enrolment
Figure 7: North America - Country wise Agoraphobia Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Agoraphobia Clinical Trials and Enrolment
Figure 9: Agoraphobia Clinical Trials by Phase
Figure 10: Agoraphobia Clinical Trials by Trial Status
Figure 11: Agoraphobia Clinical Trials by Type
Figure 12: Agoraphobia Clinical Trials by Sponsor Type
Figure 13: Agoraphobia Clinical Trials by Leading Sponsors
Figure 14: Agoraphobia Average Enrollment by Phase
Figure 15: Agoraphobia Average Enrollment by Trial Status
Figure 16: Agoraphobia Average Enrollment by Type
Figure 17: Agoraphobia- Average Enrolment by Type of Sponsors
Figure 18: Agoraphobia- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Agoraphobia Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Agoraphobia Clinical Trials and Enrolment
Table 5: Europe - Country wise Agoraphobia Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Agoraphobia Clinical Trials and Enrolment
Table 7: North America - Country wise Agoraphobia Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Agoraphobia Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Agoraphobia Average Enrollment by Phase
Table 15: Agoraphobia Average Enrollment by Trial Status
Table 16: Agoraphobia Average Enrollment by Type
Table 17: Agoraphobia- Average Enrolment by Type of Sponsors
Table 18: Agoraphobia- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3
  • Alfred E. Tiefenbacher GmbH & Co KG
  • Bluefish Pharmaceuticals AB
  • Dexcel PT Holdings Ltd
  • Eli Lilly and Co
  • Mylan NV
  • Pfizer Inc
  • Syneos Health Inc
  • The Lundbeck Foundation
  • Torrent Pharmaceuticals Ltd
  • Wockhardt Ltd
Note: Product cover images may vary from those shown
Adroll
adroll